Free shipping on all orders over $ 500

EDP-305

Cat. No. M22512

All AbMole products are for research use only, cannot be used for human consumption.

EDP-305 Structure
Synonym:

EDP305

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC50 values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 can be used for the research of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). EDP-305 (0-5 μM, 16 h) increases the expression of the FXR target gene, SHP, and downregulates CYP7A1 expression in HepaRG hepatocytes. 

EDP‐305 (0-30 mg/kg, Oral gavage, daily for 2 weeks) reduces serum markers of liver injury, and reduces liver fibrosis in a dose-dependent manner in BDL rats. EDP‐305 (0-30 mg/kg, Oral gavage, daily for 6 weeks) reduces liver fibrosis in a dose-dependent manner in CDAHFD mice.

Chemical Information
Molecular Weight 630.92
Formula C36H58N2O5S
CAS Number 1933507-63-1
Solubility (25°C) DMSO 100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Alaa Ahmad, et al. Clin Transl Sci. Assessment of drug-drug interaction potential with EDP-305, a farnesoid X receptor agonist, in healthy subjects

[2] Claus Kremoser. J Hepatol. FXR agonists for NASH: How are they different and what difference do they make?

[3] Ping An, et al. Liver Int. A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction

[4] Shen Li, et al. FASEB J. The farnesoid X receptor agonist EDP-305 reduces interstitial renal fibrosis in a mouse model of unilateral ureteral obstruction

Related Farnesoid X Receptor Products
GW4064

GW4064 is a selective, non-steroidal agonist of the orphan nuclear receptor FXR with EC50 of 15 nM.

WAY-362450 (Turofexorate isopropyl)

WAY-362450 (Turofexorate isopropyl; XL335) is a potent, selective, and orally bioavailable FXR agonist with EC50 of 4 nM.

Chenodeoxycholic acid

Chenodeoxycholic acid is an epimer of ursodeoxycholic acid, which inhibits the production of cholesterol in the liver and absorption in the intestines.

Obeticholic Acid (INT-747)

Obeticholic Acid (INT-747) is a potent, orally active, selective farnesoid X receptor (FXR) agonist with an EC50 of 99 nM.May be used in studies related to non-alcoholic steatohepatitis (NASH).

Sevelamer HCl

Sevelamer HCl is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption.

  Catalog
Abmole Inhibitor Catalog




Keywords: EDP-305, EDP305 supplier, Farnesoid X Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.